Archive | April, 2017

Boston Innovation Capital Celebrates Our One Year Anniversary

27 Apr

By Colin Widen, CEO, Boston Innovation Capital

Boston Innovation Capital (BIC), a wholly owned subsidiary of LSN Holdings, became a FINRA-registered broker dealer in 2016. BIC works alongside LSN’s other two divisions (LSN’s Investor Platform and Company Platform, and the RESI Conference Group) to support early stage companies in forging connections with investors, major pharma firms and other strategic players in the life science world.

With a year of operations under our belt, BIC has expanded its services to support both startups and investors in building early stage connections based on a good fit between buyers and sellers of new life science innovations.

BIC was founded to create and execute global fundraising campaigns for startups in the biotech, medical devices, diagnostics and healthcare IT sectors. This was a logical start for the firm due to BIC’s relationship with Life Science Nation. The conversation that LSN maintains with the industry via the RESI events and the LSN Investor Platform creates a close relationship with investors and deep awareness of the fundraising landscape.

These relationships have also given BIC the capacity to offer buy side services. BIC can often make confidential inquiries to investors regarding their portfolio companies. This gives BIC access to tens of thousands of private companies that are extremely difficult to source. Not only does BIC get access via these investors but they receive a potential introduction by in many cases an investor who has a board seat. This puts BIC in a unique position to represent entities looking to license or acquire assets.

LSN’s unique position in the early stage space, and the range of capabilities we have developed, provide a strong foundation for a sourcing and ranking service for clients interested in investment/acquisition opportunities. LSN is uniquely positioned to rapidly identify and assess technology assets for clients focusing on any disease area of interest. We operate at the intersection of many North American and European channels of early stage life science technology assets.

LSN has deep relationships with Big Pharma players, large global CRO’s and other service providers who are all long-term clients. LSN owns and curates one of the top early stage company databases in the world and sells this database to these partners who use it to source early stage life science technology. This global positioning, along with the appearance of exciting new companies/technologies at our RESI meetings and deep relationships with our partners (pharma, NIH, investors) enables LSN to provide our clients with a comprehensive view of their interest areas.

The Sourcing and Ranking Service (SRS) provides clients with a comprehensive opportunity to make the sourcing process super efficient. Starting with a detailed assessment of the clients’ investment interests, LSN will conduct a global search for assets in that interest area; will vet and rank the most relevant assets; will provide the client with a deep dive analysis of the companies holding the top 10 to 20 assets. SRS is designed to provide clients with a rapid, end-to-end business development research capability that will enable them to more quickly access the assets they are most interested in.

If you’re interested in how to source, vet and rank new assets, stay tuned, because we’ll cover this in depth in next week’s newsletter. We look forward to building on our resources and relationships in the years to come, and offering both startups and investors more support in finding the right match.

Branding Your Life Science Startup – The Logo and Tagline Are More Important Than You Might Think

27 Apr

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Having a clear and consistent identity and message—or brand—that differentiates you is a critical requirement in establishing yourself as an investible identity to your prospective capital providers.

Many life science executives falsely believe that only consumer goods companies must invest in branding. Many also believe that their technology is so compelling that it will speak for itself. The reality is that branding is equally important in the life sciences, especially when it comes to raising capital, and that selling even the best of products takes some work.

Although you’re communicating with a small and highly educated audience, branding influences the choices they make. Your brand is what you present to the world. In creating it, you must ask yourself how you want to present your company and product and how you want to be seen and perceived. A logo may seem like a trivial component, but it’s actually an opportunity for you to create an image in an investor’s mind.

The goal of logo development is to create one that embodies the identity of your firm. Your logo is a symbolic representation of what your firm is all about, and it (like your marketing collateral) needs to be clear, crisp, and obvious. Too often, entrepreneurs will pick a logo that is inscrutable to an investor (for example, a complex molecular diagram) without thinking about it from a marketing perspective. You must take the time to consider what differentiates your company from the rest of the marketplace, what values your company holds, and what message you are trying to send. If you take the time to think through these questions, you’ll be able to develop a logo that is a strong and simple representation of the image you are striving to achieve in the marketplace.

Right below your logo should be your tagline. A tagline communicates in one crisp statement who you are and what you do. A common mistake people make is writing taglines that are general and nondescriptive rather than crisp and compelling. Examples of poor ones are “Moving Science Forward,” “Next Generation Solutions,” and “Creating New Therapies.” These don’t say anything specific about what the company does. A great tagline explains precisely what you do in a few words and starts to provide the context for who the company is.

Some examples of successful taglines include “Inventors of a Novel, Safe Anti-Cancer Agent” and “Anti-Infective Preventing the Replication of the Hep B Virus.” Life Science Nation’s tagline is “Connecting Products, Services & Capital.” The tagline needs to capture the essence of what your company does so that the reader has a general idea of what you are about. In the case of the latter example, the company name “Life Science Nation defines the arena the company plays in. The tagline informs the reader of the company’s role within that space.

Are your logo and tagline up to the task of representing your brand? LSN is launching a contest to find the best startup branding in the life sciences. Send in your logo and tell us the 5-7 word tagline for your startup, and we’ll feature the best submissions in a future edition of this newsletter, which will go out to 40,000 readers around the world.

Key Stakeholders Share the Value of RESI for Early Stage Investors and Startups

27 Apr

By Natasha Eldridge, RESI Conference Manager, LSN

natasha-wp-new

In San Diego on June 19th, the Redefining Early Stage Investments (RESI) Conference will bring a new, early stage focused discussion venue for startups and investors who are visiting BIO week and want more opportunities to connect. What makes RESI different? At our last event, RESI on MaRS in Toronto, we asked our key stakeholders this question and here’s what they told us.

Ying Tam – Head of Digital Health – MaRS Discovery District

“All the research says that one of the critical elements for an entrepreneur ecosystem, especially in health, is funding and investment. It takes a long time to nurture a health company, to get it to market and commercialization and scale. So, investment is critical for the development of a startup in health. RESI brings in a whole set of investors from across North America and across the world.”

Rebecca Yu – Head of JLABS @ TorontoJohnson & Johnson Innovation JLABS

“RESI attracts many repeat attendees, and that speaks to me that there’s a story, there’s something here. There’s great stuff happening here for entrepreneurs. There’s early stage companies from across Canada, from pharmaceuticals to medical devices to consumer health, and of course there’s a big digital health and AI presence here in Toronto. That’s why JLABS and J&J are here. We play in all the sectors, we partner with different groups within this ecosystem, and we see LSN/RESI as a key partner as well, to bring investors to this ecosystem.”

Richard Soll – Senior Vice President, International Discovery Service Unit – WuXi AppTec

“The RESI conference is an opportunity to help out these early stage companies such that they can achieve inflection points. If I can identify companies early, then I might become a vendor of choice for them. Getting in early becomes an important objective for me. When I come to a conference like RESI, I come to these early stage companies who are really looking for partnering with investors here, but also get an opportunity to introduce WuXi to them as well.”

RESI attendees can book up to 16 meetings with investors in one day, right at the start of BIO Week. If you want to take this opportunity to start your BIO with a bang, register now.

Hot Investor Mandate 1: Corporate VC Invests in Repurposed Drugs and New Combinations in CNS and Respiratory Diseases

27 Apr

The venture capital arm of a global pharmaceutical firm invests in early stage ideas with breakthrough technologies addressing major unmet medical needs. The firm seeks to make equity investments in Seed and Series A/B rounds with an ultimate possibility of acquisition. The firm has a global mandate and is currently seeking new investment opportunities.

The firm is currently seeking to invest in early to mid-stage repurposed drugs, repositioned drugs, combination therapies, and new delivery technologies and devices for old drugs. In terms of indications, the firm is focused on CNS and respiratory diseases. The firm will prioritize 505(b)(2) opportunities.

The firm seeks companies with a strong and experienced management team. The firm may take a board seat/board observer rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: European PE Fund Invests Opportunistically in Drugs and Devices

27 Apr

A private equity firm based in Paris, France has a venture team that currently has €400M AUM. The firm mainly provides equity financing and may provide convertible loans as follow-on investments. The firm typically makes an initial investment of up to €2-3M, and up to €8M over the life of the investment, which can be start as early as seed stage. The firm preferably invests in European-based companies, and seeks to make about 2 allocations every year in the life sciences area (minority stakes).

The firm remains opportunistic in the life sciences, with a focus on drug development and medical devices. The firm is agnostic in terms of subsectors, indications and stage. Currently, the firm is active in many subsectors.

The firm seeks to acquire minority stakes in its portfolio companies. The firm is looking for companies with a talented and entrepreneurial management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: US Private Equity Firm Makes Multi-Stage Investments in Biotech and Medtech

27 Apr

A private equity group with offices on the US East and West Coasts has over $1 billion in assets under management, and is investing from a third fund of over $500 million. The firm makes both venture-stage and growth-stage equity investments, which are typically in the $10-30 million range. The firm primarily invests in North America and the European Union but may also consider opportunities in the Middle East.

The firm invests in biotechnology, medical technology, diagnostics, healthcare services, and healthcare IT. The firm is generally agnostic regarding indications. The firm invests at a range of stages, from development through to profitability, but prefers to back technologies that have attained proof of concept data.

The firm invests in both pre-revenue companies and post-revenue companies. The firm typically leads or co-leads investments, and prefers to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Healthcare Company Looking to In-License or Acquire Innovative Late Stage Drugs and Devices

27 Apr

A specialist healthcare company with offices in Europe, North America, and Australia is actively looking to in-license and acquire innovative therapeutics and medical devices that are of strategic interest. The firm is capable of making allocations ranging from £10 million to over £100 million and more for later-stage acquisitions. The firm is most interested in companies that are looking to be marketed in the United States although they are open to global opportunities as well.

The firm is interested in therapeutic assets and medical devices, particularly interventional medicine products that can be used to advance the treatment of cancer, cardiovascular, and pulmonary diseases. The firm is open to therapeutics within these areas as well as other indications, pending they are intended to be hospital products. The firm is primarily interested in small molecule therapeutics and is focused on late-stage/marketed products at the current time.

For medical devices, the firm is looking for companies that have 510K approval in oncology, vascular and pulmonary fields. The firm’s current device products include interventional oncology products used to treat patients with liver tumors, interventional vascular products used to treat patients with severe blood clots, and investigational devices for the treatment of severe emphysema.

The firm is interested in working with founding management teams prior to investment and is open to in-licensing from public and private clients.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com